Two-step CAR-T therapy for AML with CD33/CD123
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML).
- Your leukemia cells must show one or more of these markers on their surface: CLL-1, CD123, or CD33.
- You must be at least 6 months old.
- Your overall health should be fairly good—able to care for yourself and expected to live more than 3 months.
- Key organs (like heart, lungs, kidneys, liver) must be working reasonably well, as shown by recent tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This study tests a new treatment that uses your own immune cells (called CAR-T cells) to fight leukemia, followed by a stem cell transplant to help rebuild your immune system. It is designed for people with acute myeloid leukemia (AML) that has not gone away or has come back after standard treatment.
This study tests a universal CAR-T cell therapy for acute myeloid leukemia (AML), a type of blood cancer. The treatment uses specially engineered immune cells to target leukemia cells with certain markers, and the trial aims to see if it is safe and effective for patients whose leukemia has not responded to standard treatments.
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.